KAT5 and gout: Since aberrant NLRP3 inflammasome activity contributes to series of diseases including sepsis, gout, atherosclerosis, type 2 diabetes, autoimmune disorders and Alzheimer’s disease3,38, our study also indicated that targeting KAT5-NLRP3 axis may provide a potential for treatment of NLRP3 associated diseases.